Managing Your Screenings and Surveillance
At a Glance
PALB2 carriers generally need earlier, more intensive breast screening, while pancreatic surveillance depends on personal and family history. Routine ovarian screening is usually not recommended without symptoms; discuss risk-reducing surgery and report warning signs promptly.
Now that you know your PALB2 status, your medical care shifts from general wellness to specialized surveillance. The goal of this screening is twofold: to detect any changes at their earliest, most treatable stage and to provide you with peace of mind. Your specific schedule is based on consensus from major medical organizations like the National Comprehensive Cancer Network (NCCN) [1].
Breast Cancer Screening
For women and people with female breast tissue, the screening guidelines for PALB2 carriers are intensive and aim to catch breast cancer early [2].
- Breast MRI: You will typically begin annual contrast-enhanced breast MRI between the ages of 30 and 35, or 5 to 10 years before the earliest breast cancer diagnosis in your family [1]. MRI is highly sensitive and is excellent at finding small changes in dense breast tissue [3].
- Mammography: You will also begin annual mammograms (specifically 3D tomosynthesis) starting around age 30 to 40 depending on the specific guideline and your personal risk [3][4].
- Staggered Schedule: Many specialists offer a “staggered” schedule—for example, having your MRI in January and your mammogram in July—so that your breasts are being professionally imaged every six months. This is an optional coordination strategy, not a strict requirement [5][6].
- Clinical Exams: A healthcare provider should perform a clinical breast exam every 6 to 12 months [2].
For male carriers: Men with a PALB2 variant have a different, less intensive approach. You should discuss performing self-exams and having clinical breast exams during routine doctor visits, as male breast cancer risk, while elevated, is much lower than female risk [7].
Pancreatic Cancer Screening
Pancreatic screening guidelines vary, and you should have an individualized discussion with your care team about whether you qualify [8].
- Who Qualifies: Most guidelines recommend pancreatic screening if you have a PALB2 mutation and a family history of the disease. Some guidelines specify a first-degree relative (parent, sibling, child), while others include second-degree relatives or suggest considering screening regardless of family history [9][10].
- When to Start: Screening usually begins at age 50, or 10 years earlier than the age your youngest relative was diagnosed, whichever comes first [11][9].
- The Methods: Screening is performed annually using specialized imaging: either an Endoscopic Ultrasound (EUS) or a high-resolution MRI/MRCP [11][9]. These tests should be performed at high-volume centers with expertise in high-risk surveillance [2].
Why Ovarian Screening is Different
While PALB2 increases the risk of ovarian cancer, routine screening with transvaginal ultrasound (TVUS) or CA-125 blood tests is typically not recommended for women who do not have symptoms [2][12].
Research has shown that these screening tools are not effective at reducing the number of deaths from ovarian cancer [13]. They often miss early-stage disease and have a high rate of false positives, which can lead to unnecessary and invasive surgeries [14][15]. Instead of screening, most experts recommend discussing risk-reducing surgery (removal of the fallopian tubes and ovaries) once you have finished having children [2][12].
Red Flags: When to Call Your Doctor
Screening is intended for people without symptoms. If you notice any of the following “red flag” symptoms, do not wait for your next scheduled screening; contact your care team promptly for a diagnostic evaluation, even if a recent screening test was normal.
- A new, firm, or fixed lump in the breast or underarm.
- Skin changes, such as dimpling, puckering, or redness that looks like an orange peel (peau d’orange).
- Nipple retraction (turning inward) or unusual nipple discharge.
Pancreatic Red Flags [18]:
- Jaundice: Yellowing of the skin or the whites of the eyes (this requires urgent same-day evaluation).
- Unexplained weight loss or a significant loss of appetite.
- New-onset mid-back pain or upper abdominal pain that does not go away.
Ovarian Red Flags [15]:
- New, persistent, or worsening abdominal bloating or feeling “full” very quickly after eating over roughly two weeks or more.
- Pelvic or abdominal pain that occurs almost daily.
- Urgent or frequent need to urinate that is a new change for you.
Having these symptoms does not mean you have cancer, but for a PALB2 carrier, they require prompt medical investigation to rule it out [16].
Common questions in this guide
When should I start breast MRI and mammograms if I have a PALB2 variant?
Do all people with a PALB2 mutation need pancreatic cancer screening?
What tests are used to screen for pancreatic cancer in PALB2 carriers?
Should people with a PALB2 variant and no symptoms get ovarian cancer screening?
Is it helpful to alternate my PALB2 breast MRI and mammogram?
What symptoms should prompt a PALB2 carrier to call the doctor?
One line in your results can change your plan.
A family history of pancreatic cancer can decide whether annual pancreatic screening is recommended; your care team can help settle this. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on PALB2-related cancer predisposition.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
Hudson L, Gower N, Lenarcic S, et al.
Annals of surgical oncology 2020; (27(7)):2248-2254 doi:10.1245/s10434-019-08191-0.
PMID: 31974710 - 2
Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Tischkowitz M, Balmaña J, Foulkes WD, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1416-1423 doi:10.1038/s41436-021-01151-8.
PMID: 33976419 - 3
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review.
Masanam MK, Pitcher CW, Sogunro O, et al.
Translational breast cancer research : a journal focusing on translational research in breast cancer 2022; (3()):37 doi:10.21037/tbcr-22-33.
PMID: 38751533 - 4
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP, Geuzinge HA, Stout NK, et al.
JAMA oncology 2022; (8(4)):587-596 doi:10.1001/jamaoncol.2021.6204.
PMID: 35175286 - 5
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
Esserman LJ, Fiscalini AS, Naeim A, et al.
JAMA 2026; (335(9)):763-774 doi:10.1001/jama.2025.24784.
PMID: 41385349 - 6
Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.
Shieh Y, Heise RS, Madlensky L, et al.
JAMA oncology 2026; (12(8)):875-880 doi:10.1001/jamaoncol.2026.2091.
PMID: 42218736 - 7
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Yang X, Leslie G, Doroszuk A, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(7)):674-685 doi:10.1200/JCO.19.01907.
PMID: 31841383 - 8
Pancreatic Cancer Surveillance: Who, When, and How.
Dudley B, Brand RE
Current treatment options in gastroenterology 2019; (17(4)):681-691 doi:10.1007/s11938-019-00247-0.
PMID: 31761968 - 9
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Aslanian HR, Lee JH, Canto MI
Gastroenterology 2020; (159(1)):358-362 doi:10.1053/j.gastro.2020.03.088.
PMID: 32416142 - 10
Outcomes of pancreatic cancer surveillance among high-risk individuals at a tertiary care academic center.
Lee AA, Twoy A, Siddappa P, et al.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2026; (26(5)):719-723 doi:10.1016/j.pan.2026.06.006.
PMID: 42399188 - 11
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
Goggins M, Overbeek KA, Brand R, et al.
Gut 2020; (69(1)):7-17 doi:10.1136/gutjnl-2019-319352.
PMID: 31672839 - 12
Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.
Liu YL, Breen K, Catchings A, et al.
JCO oncology practice 2022; (18(3)):201-209 doi:10.1200/OP.21.00382.
PMID: 34582274 - 13
Ovarian Cancer Prevention and Screening.
Menon U, Karpinskyj C, Gentry-Maharaj A
Obstetrics and gynecology 2018; (131(5)):909-927 doi:10.1097/AOG.0000000000002580.
PMID: 29630008 - 14
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.
, Grossman DC, Curry SJ, et al.
JAMA 2018; (319(6)):588-594 doi:10.1001/jama.2017.21926.
PMID: 29450531 - 15
Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
Obstetrics and gynecology 2017; (130(3)):e146-e149 doi:10.1097/AOG.0000000000002299.
PMID: 28832487 - 16
Clinically Malignant Breast Lesion in an Adolescent Girl: A Case Report.
Sosnowska-Sienkiewicz P, Mańkowski P
Clinics and practice 2021; (11(3)):435-440 doi:10.3390/clinpract11030058.
PMID: 34287288 - 17
Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides.
Yaghoobi R, Talaizade A, Lal K, et al.
The Journal of clinical and aesthetic dermatology 2015; (8(8)):47-51.
PMID: 26345728 - 18
When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature.
Derouane F, Yombi JC, Baurain JF, et al.
Acta clinica Belgica 2020; (75(4)):301-307 doi:10.1080/17843286.2019.1607990.
PMID: 31035903
This page is for informational purposes only and does not constitute medical advice. Your care team should tailor PALB2 screening, surveillance, and risk-reducing options to your personal and family history.